Skip to Content
MilliporeSigma
All Photos(3)

Key Documents

View All Documentation

O7125

Sigma-Aldrich

L-Ornithine L-aspartate salt

≥98% (TLC)

Synonym(s):

(S)-2,5-Diaminopentanoic acid L-aspartate salt

Sign Into View Organizational & Contract Pricing
All Photos(3)

About This Item

Empirical Formula (Hill Notation):
C9H19N3O6
CAS Number:
3230-94-2
Molecular Weight:
265.26
EC Number:
221-772-7
MDL number:
MFCD00058084
UNSPSC Code:
12352209
PubChem Substance ID:
329818920
NACRES:
NA.26

Product Name

L-Ornithine L-aspartate salt, powder

assay

≥98% (TLC)

Quality Level

200

form

powder

color

white to off-white

storage temp.

2-8°C

SMILES string

NCCC[C@H](N)C(O)=O.N[C@@H](CC(O)=O)C(O)=O

InChI

1S/C5H12N2O2.C4H7NO4/c6-3-1-2-4(7)5(8)9;5-2(4(8)9)1-3(6)7/h4H,1-3,6-7H2,(H,8,9);2H,1,5H2,(H,6,7)(H,8,9)/t4-;2-/m00/s1

InChI key

IXUZXIMQZIMPSQ-ZBRNBAAYSA-N

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

L-Ornithine L-aspartate is a metabolite of arginine degradation by arginase. It has been shown to reduce blood ammonia concentrations by increasing ammoniadetoxification in the muscle and reducing the severity of hepatic encephalopathy in cirrhosis.

Other Notes

Product of arginine degradation by arginase

Storage Class

11 - Combustible Solids

wgk_germany

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000369173
0000369173
SLBW4848
SLBQ1192V
SLBN4186V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

B M Datsenko et al.
Klinichna khirurhiia, (4)(4), 9-12 (2013-07-31)
Comparative analysis of results of examination and treatment of 54 patients, suffering obturation jaundice syndrome, is presented. The presence and severity of hepatic dysfunction was determined in accordance to indices of cytolysis and cholestasis syndromes, and its severity--in accordance to
Treatment of hyperammonemia in liver failure: a tale of two enzymes.
Rajiv Jalan et al.
Gastroenterology, 136(7), 2048-2051 (2009-05-05)
Suzanna Ndraha et al.
Acta medica Indonesiana, 42(3), 158-161 (2010-08-21)
Excessive protein intake can cause hepatic encephalopathy (HE). Restricting protein in HE is becoming a controversy, because it can worsen malnutrition. This article reports the case of an under nourishment HE which is treated with L-ornithine-L-aspartate (LOLA) and given appropriate
Mark J W McPhail et al.
Neurology, 80(11), 1041-1047 (2013-02-22)
To measure changes in psychometric state, neural activation, brain volume (BV), and cerebral metabolite concentrations during treatment of minimal hepatic encephalopathy. As proof of principle, 22 patients with well-compensated, biopsy-proven cirrhosis of differing etiology and previous minimal hepatic encephalopathy were
Abhijit Das et al.
Neurochemical research, 45(6), 1438-1450 (2020-05-20)
L-Ornithine-L-aspartate (LOLA), a crystalline salt, is used primarily in the management of hepatic encephalopathy. The degree to which it might penetrate the brain, and the effects it might have on metabolism in brain are poorly understood. Here, to investigate the
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service